HDL Therapeutics, Inc. signed a non-binding letter of intent to acquire Swiftmerge Acquisition Corp. (NasdaqGM:IVCP) in a reverse merger transaction on April 24, 2023. Completion of a business combination with HDL Therapeutics is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the board and shareholders of both Swiftmerge and HDL Therapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.8 USD | +0.28% | +0.09% | -0.64% |
1st Jan change | Capi. | |
---|---|---|
-0.64% | 73.87M | |
+181.49% | 6.73B | |
+18.11% | 1.17B | |
+2.19% | 982M | |
+41.91% | 872M | |
+22.24% | 799M | |
+11.31% | 675M | |
+1.72% | 664M | |
+43.66% | 654M | |
-.--% | 600M |
- Stock Market
- Equities
- IVCP Stock
- News Swiftmerge Acquisition Corp.
- HDL Therapeutics, Inc. signed a non-binding letter of intent to acquire Swiftmerge Acquisition Corp. in a reverse merger transaction.